FILTER

Refine your search with the following facets to narrow down your results.

14 Current news of Cambrex

Cambrex Completes Sale of Two Non-Strategic Human Health Facilities

01-Nov-2006 - Cambrex Corporation announced that the sale of its Human Health facilities in Cork, Ireland, and Landen, Belgium, to International Chemical Investors S.A. II (ICIG) of Luxembourg had been completed on October 27, 2006. "The completion of this transaction represents an important step in our ...

Belgium Ireland

Cambrex Corporation and Cytori Therapeutics Enter Into Collaboration to Provide Adipose Derived Stem Cell Research Products

16-Jun-2006 - Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, and Cytori Therapeutics announced that they have entered into a strategic marketing agreement to provide adipose-derived stem cell products globally for use in basic and translational bioresearch. Under the terms of the ...

progenitor cells stem cells StemCells

Cambrex Licenses Cell Line to Chugai Pharmaceutical Co.

23-Feb-2006 - Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex, announced that its client Chugai Pharmaceutical Co., Ltd. completed their assessment of certain of its Clonetics(R) Conditionally Immortalized Cell Lines under the previously announced evaluation license and signed a one-year ...

cell lines Japan license agreements +2

Geron and Cambrex Announce Contract Manufacturing Arrangement for cGMP Production of GRNVAC1 for Clinical Trials

15-Feb-2006 - Geron Corporation and Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, announced an agreement for the manufacture of Geron's GRNVAC1 telomerase vaccine. The agreement provides for the transfer of Geron's vaccine production process to Cambrex and the cGMP manufacture of ...

clinical trials dendritic cells immunology +4

Cambrex Acquires Cutanogen Corporation

07-Feb-2006 - Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, announced it has entered into a purchase agreement for all of the stock of Cutanogen Corporation, a privately-held biotechnology company that is focused on products used to treat patients with severe burns. The Company ...

biotechnology regulatory approval

Cambrex Licenses Cell Lines to Chugai Pharmaceutical Co.

05-Oct-2005 - Cambrex Bioscience Walkersville, Inc., a subsidiary of Cambrex Corporation, announced that they have signed an evaluation license agreement with Chugai Pharmaceutical Co., Ltd. for the use of certain Cambrex Clonetics® Conditionally Immortalized Cell Lines. The licensed cell lines were created ...

cardiovascular diseases cell lines cell-based assays +5

David R. Bethune Joins the Cambrex Board of Directors

08-Jun-2005 - Cambrex Corporation announced that David R. Bethune was elected to the Cambrex Board of Directors on June 2, 2005. David R. Bethune most recently was Chairman and Chief Executive Officer of Atrix Laboratories, a drug delivery and product development company, where he has been a director of the ...

drug delivery laboratories

New Gene Expression Data for Cambrex Primary Cells

06-Jun-2005 - Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation, announced the availability of gene expression data and summary analyses for several primary human cell types. A comparison of the gene expression patterns between the undifferentiated and differentiated states revealed ...

Expression fat cells gene expression

Cambrex Licenses Powerful Technologies for Conditionally Immortalized Cells For Use in Drug Discovery

21-Jan-2005 - Cambrex Corporation announced that its subsidiary Cambrex Bio Science Wokingham, Ltd. has signed an agreement for the purchase of conditionally immortalized cell lines, related intellectual property and equipment of Xcellsyz Limited, Newcastle Upon Tyne, United Kingdom. Cambrex Bio Science ...

cardiovascular diseases cell lines license agreements +3

DOR BioPharma and Cambrex Enter into a Development and Manufacturing Process Agreement for RiVax(TM)

20-Jan-2005 - DOR BioPharma, Inc. and a subsidiary of Cambrex Corporation have entered into an agreement with respect to process development for potential large scale production of DOR's proprietary ricin vaccine, RiVax(TM). Under the agreement, Cambrex will provide process development and cGMP (current Good ...

process development services toxicity +1